UBL3

Across TCGA pan-cancer cohorts, UBL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBL3 data layer compared with 19 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBL3 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

PDAC, OV, and LUAD are the cancer types where UBL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.312	0.574	.022	15	view →
OV	DFS	Tertile	All	0.835	0.466	.026	12	view →
LUAD	DFS	Quartile	All	0.866	0.997	.035	1	view →
CCRCC	DFS	Median	II,III,IV	0.892	1.000	.047	1	view →
LSCC	DFS	Quartile	All	0.966	1.000	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBL3–PDAC (OS)

Open the PDAC breakdown →